The pre-clinical biotechnology company, Indaptus Therapeutics, is revolutionizing cancer and infectious disease treatment with its proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. Its pre-clinical candidate, Decoy20, has demonstrated single-agent activity and durable anti-tumor responses in standard pre-clinical models against colorectal, hepatocellular, pancreatic carcinoma, and non-Hodgkin's lymphoma in combination settings.